Endocrinology · Growth-Hormone Research
Ipamorelin
GH axis pharmacology researchGHRH + GHRP additivePulsatile GH release research
USP-grade·99%+ purity by HPLC·Third-party verified·For research & licensed clinical use·Referenced in 2+ peer-reviewed studies
cGMP facility · Third-party tested · Cold-chain shipping · 24-hour COA on request
Reference Compound
Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R1a) agonist — the same receptor targeted by endogenous ghrelin. The pentapeptide binds GHS-R1a on pituitary somatotrophs and hypothalamic neurons, triggering Gq-mediated phospholipase C activation and pulsatile growth hormone release.
Latest lot released May 22PAP-1510-26
At a Glance
Show
- CAS
- 170851-70-4
- MW
- 711.85 Da
- Sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Half-life
- ~2 hours
- Route
- Subcutaneous in research
- Storage
- −20°C long term; 2–8°C short term (weeks). Protect from light.
Quality Documentation
Lot PAP-IPAMOR-240118-A01 — Reference
Overview
Field of Medicine — Endocrinology · Growth-Hormone Research
Field of Medicine
Endocrinology — Growth Hormone Secretagogue Research.
Background
Ipamorelin is a selective pentapeptide growth-hormone secretagogue and ghrelin-receptor (GHSR-1a) agonist. It was developed to stimulate pulsatile growth-hormone release without meaningful effects on cortisol, prolactin, or aldosterone — distinguishing it from earlier GHRPs.
Mechanism of Action
Ipamorelin binds the ghrelin/growth-hormone secretagogue receptor on pituitary somatotrophs, triggering a clean, pulsatile release of endogenous growth hormone that mirrors physiologic patterns more closely than continuous GH administration.
Research Applications
- GH-axis pharmacology research.
- Body-composition and lean-mass studies.
- Bone-density and recovery models.
- Comparative GHS receptor research.
Reference Compound
Ipamorelin